Abingworth’s Cymabay Therapeutics CBAY Stock Holding History

Abingworth’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$822K	Hold	131,036	–	–	0.27%	15
2022 Q3	$457K	Hold	131,036	–	–	0.16%	15
2022 Q2	$385K	Hold	131,036	–	–	0.12%	17
2022 Q1	$406K	Hold	131,036	–	–	0.12%	18
2021 Q4	$442K	Hold	131,036	–	–	0.11%	18
2021 Q3	$478K	Hold	131,036	–	–	0.11%	18
2021 Q2	$571K	Hold	131,036	–	–	0.18%	17
2021 Q1	$595K	Hold	131,036	–	–	0.21%	15
2020 Q4	$752K	Hold	131,036	–	–	0.26%	13
2020 Q3	$947K	Hold	131,036	–	–	0.2%	14
2020 Q2	$456K	Hold	131,036	–	–	0.13%	15
2020 Q1	$191K	Hold	131,036	–	–	0.13%	15
2019 Q4	$256K	Hold	131,036	–	–	0.12%	14
2019 Q3	$670K	Hold	131,036	–	–	0.42%	11
2019 Q2	$937K	Hold	131,036	–	–	0.36%	11
2019 Q1	$1.74M	Hold	131,036	–	–	1.56%	10
2018 Q4	$1.03M	Sell	131,036 -142,381	-52%	-$1.36M	0.94%	14
2018 Q3	$3.03M	Hold	273,417	–	–	1.8%	9
2018 Q2	$3.67M	Hold	273,417	–	–	2.09%	8
2018 Q1	$3.55M	Sell	273,417 -873,660	-76%	-$10.9M	2.21%	7
2017 Q4	$10.6M	Sell	1,147,077 -395,645	-26%	-$3.38M	7.65%	4
2017 Q3	$12.4M	Sell	1,542,722 -57,278	-4%	-$387K	8.6%	4
2017 Q2	$9.22M	Hold	1,600,000	–	–	7.33%	4
2017 Q1	$6.86M	Hold	1,600,000	–	–	5.11%	4
2016 Q4	$2.72M	Hold	1,600,000	–	–	2.27%	7
2016 Q3	$3.1M	Hold	1,600,000	–	–	2.98%	10
2016 Q2	$2.8M	Hold	1,600,000	–	–	2.93%	10
2016 Q1	$2.16M	Hold	1,600,000	–	–	2.01%	12
2015 Q4	$2.67M	Hold	1,600,000	–	–	1.61%	13
2015 Q3	$3.07M	Buy	+1,600,000	New	+$4.36M	1.79%	10

Other funds holding CBAY

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Abingworth's CBAY Position: Q4 2022 in Review

Abingworth held its Cymabay Therapeutics (CBAY) position steady in Q4 2022 at 131,036 shares worth $822K. The position accounts for 0.27% of the portfolio, ranked #15.

Abingworth first reported a position in CBAY in Q3 2015 and has held it in 30 quarters since. The position peaked at $12.4M in Q3 2017. 118 funds tracked by Wall St. Rank hold CBAY as of Q4 2022.

Abingworth held 131,036 shares of Cymabay Therapeutics worth $822K as of Q4 2022.
Abingworth left its Cymabay Therapeutics share count unchanged in Q4 2022.
Cymabay Therapeutics made up 0.27% of Abingworth's portfolio in Q4 2022, its #15 holding.
Abingworth first reported a position in Cymabay Therapeutics in Q3 2015 and has held it in 30 quarters since.
Abingworth's Cymabay Therapeutics position peaked at $12.4M in Q3 2017.
118 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2022.

Based on Abingworth's 13F filing for Q4 2022, filed 10 Feb 2023.